Uhlmann Packaging Systems Joins Serialization Standardization Group

Article

PTSM: Pharmaceutical Technology Sourcing and Management

PTSM: Pharmaceutical Technology Sourcing and ManagementPTSM: Pharmaceutical Technology Sourcing and Management-05-02-2017
Volume 12
Issue 5

Uhlmann Packaging Systems joined the OPC Foundation’s Open Serialization Communication Standard (OPEN-SCS) Working Group.

Uhlmann Packaging Systems has become a member of the Open Serialization Communication Standard (OPEN-SCS) Working Group. More than 20 suppliers and pharmaceutical manufacturers are currently represented in the international working group, which is developing a communication standard for various serialization and aggregation applications together with the OPC Foundation. The members are working together on specifications governing uniform interfaces to facilitate simpler data exchange between the various operation levels­-between level 2 (components) and level 3 (line control), or between level 3 and level 4 (site management), for example.

 

“Every provider has used its own communication standard up to now. Pharmaceutical manufacturers frequently cooperate with different service providers at different levels. As a result, the interfaces always have to be adapted individually. Standardized interfaces will make life substantially easier for our customers. We want to make our contribution here,” said Kathrin Günther, team leader Sales Support Software & Automation at Uhlmann, in a press release. “Participation in the working group not only keeps us on the ball, but also allows us to help set the pace in the future.”

 

The OPEN-SCS Working Group was initiated in 2014 by the OPC Foundation, a union of more than 450 companies, which defines common standards for industrial automation. In addition to Uhlmann, the OPEN-SCS Working Group includes pharmaceutical companies and systems suppliers such as Abbott, Pfizer, Roche, and Teva.

 

Source: Uhlmann Packaging Systems

 

Recent Videos
Behind the Headlines episode 6
CPHI Milan 2024: Highlighting the Benefits of Integrated Services
Behind the Headlines episode 5
Buy, Sell, Hold: Cell and Gene Therapy
Related Content